Stock Price & Analysis

The S1 support level for PASG Stock is $0.57 ,The R1 resistant level for PASG Stock is $0.63.

As of the end of day on 2025-02-05, the price of PASG Stock was $0.6.

The target price for PASG Stock according to analyst rating is 8.00, with the highest price target at 13.00 and the lowest at 4.00. Analysts have a Strong Buy rating on PASG Stock overall.

The market cap of PASG is $37.1M.

Passage Bio, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing transformative therapies for central nervous system (CNS) disorders. Its first product candidate, PBGM01, utilizes a AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal beta-galactosidase (B-gal), for GM1. Its second product candidate, PBFT02, utilizes an AAV1 capsid to deliver to the brain a functional GRN gene encoding progranulin (PGRN), for FTD caused by progranulin deficiency (FTD-GRN). The Company has two programs in the research stage: PBAL05 for amyotrophic lateral sclerosis (ALS), and an unnamed program for Huntington’s disease. PBAL05 is targeting patients with ALS who have a gain-of-function mutation in the C9orf72 gene. It also has an exploratory research program for larger non-monogenic indications, which is focused on temporal lobe epilepsy (TLE).

PASG has a total of 58 employees.